ARTICLE | Company News
KalVista, Juvenile Diabetes Research Foundation International (JDRF) deal
January 16, 2012 8:00 AM UTC
KalVista and the not-for-profit partnered to develop KalVista's KVD001, a preclinical intravitreal plasma kallikrein inhibitor to treat diabetic macular edema (DME). KalVista is eligible for up to $...